FDA Issues Recall For Several Medications Containing Valsartan

On July 13, the U.S. Food and Drug Administration (FDA) announced the voluntary recall of several drugs containing the active ingredient valsartan, used to treat high blood pressure and heart failure, due to an impurity, N-nitrosodimethylamine (NDMA), classified as a probable human carcinogen, found in the recalled products.

The FDA is actively investigating NDMA levels in the recalled products and assessing effects on patients who have been taking the drugs. Patients taking the recalled products should continue taking the medicines as prescribed until they have a replacement product. Read a full list of affected products.

Clinical Topics: Heart Failure and Cardiomyopathies, Prevention, Acute Heart Failure, Hypertension

Keywords: ACC Advocacy, United States Food and Drug Administration, Product Recalls and Withdrawals, Hypertension, Heart Failure, Carcinogens


< Back to Listings